Pharmacotherapy of Bone Loss in Postmenopausal Women: Focus on Denosumab

ABSTRACT: Denosumab is a human monoclonal antibody against RANKL. This antibody decreases bone turnover markers and increases bone mineral density (BMD) in postmenopausal women. In phase 3 studies including more than 1100 women, denosumab achieved greater increases in lumbar spine, total hip, distal...